For prostate cancer, published guidelines recommend routine posttreatment surveillance using PSA testing; however, because of lack of empiric evidence, guideline recommendations vary from every 3 months to every 12 months surveillance, a 4-fold difference (3). The gene discussed is KLK3; the disease is prostate cancer.